Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United StatesVANCOUVER, ...

Antibodies are a critical feature of the human adaptive immune response. New immunotherapies require the production of selective and non-autoimmunogenic antibodies. These engineered antibodies can ...

The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...

Osaka, Japan – Pancreatic cancer is an aggressive disease with few available treatments. Thankfully, researchers are hard at work to improve treatment options, and researchers from Japan have now ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (TWST) (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. Breast cancer frequently overexpresses the product of the ...

Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 ...

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses. Harnessing that ...

Researchers have developed an antibody that prevents the activation of the Dickkopf 1-Cytoskeleton-associated protein 4 (DKK1-CKAP4) pathway, which is important for tumor growth in several cancers, ...